1. Home
  2. MBIO vs NCNA Comparison

MBIO vs NCNA Comparison

Compare MBIO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.62

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.34

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIO
NCNA
Founded
2015
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.7M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
MBIO
NCNA
Price
$0.62
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.0K
61.8K
Earning Date
05-13-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.03
52 Week High
$2.19
$10.00

Technical Indicators

Market Signals
Indicator
MBIO
NCNA
Relative Strength Index (RSI) 42.39 36.15
Support Level $0.64 $1.27
Resistance Level $0.82 $2.27
Average True Range (ATR) 0.05 0.12
MACD -0.01 0.01
Stochastic Oscillator 26.01 27.66

Price Performance

Historical Comparison
MBIO
NCNA

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

Share on Social Networks: